Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Genmab A/S ADR
(NQ:
GMAB
)
28.38
+0.25 (+0.89%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Genmab A/S ADR
< Previous
1
2
3
4
5
6
7
Next >
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
March 28, 2024
Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout.
Via
Chartmill
Analyst Ratings For Genmab
March 26, 2024
Via
Benzinga
NASDAQ:GMAB is showing good growth, while it is not too expensive.
March 21, 2024
For those who appreciate growth without the sticker shock, GENMAB A/S -SP ADR (NASDAQ:GMAB) is worth considering.
Via
Chartmill
Why NASDAQ:GMAB Is a Promising High-Growth Stock in the Midst of Consolidation.
March 05, 2024
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
February 29, 2024
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.
Via
Chartmill
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
February 27, 2024
From
Genmab A/S
Via
Business Wire
4 Analysts Assess Genmab: What You Need To Know
February 20, 2024
Via
Benzinga
Earnings Outlook For Genmab
February 13, 2024
Via
Benzinga
NASDAQ:GMAB, a strong growth stock, setting up for a breakout.
February 08, 2024
Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock?
Via
Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
February 08, 2024
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.
Via
Chartmill
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
February 02, 2024
From
Genmab A/S
Via
Business Wire
Cracking The Code: Understanding Analyst Reviews For Genmab
January 29, 2024
Via
Benzinga
What's Going On With Danish Healthcare Firm Genmab Stock?
January 23, 2024
Genmab's legal update on Darzalex: Arbitrator dismisses bid for milestone payments. Despite this, diverse revenue sources, including royalty agreements, contribute to strong growth.
Via
Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:GMAB.
January 18, 2024
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via
Chartmill
9 Analysts Have This to Say About Genmab
November 28, 2023
Via
Benzinga
NASDAQ:GMAB is not too expensive for the growth it is showing.
November 10, 2023
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
Via
Chartmill
Analyst Expectations for Genmab's Future
November 08, 2023
Via
Benzinga
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
January 09, 2024
From
Genmab A/S
Via
Business Wire
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
January 09, 2024
From
Pfizer Inc.
Via
Business Wire
NASDAQ:GMAB, a strong growth stock, setting up for a breakout.
November 01, 2023
GENMAB A/S -SP ADR (NASDAQ:GMAB)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via
Chartmill
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank.
December 26, 2023
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Via
Chartmill
Oracle Reports Weak Sales, Joins Kinetik, Lucid Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
December 12, 2023
U.S. stock futures were higher this morning, with the Dow Jones futures gaining over 50 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
December 09, 2023
From
Genmab A/S
Via
Business Wire
In the world of growth stocks, NASDAQ:GMAB shines as a value proposition.
December 05, 2023
Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB).
Via
Chartmill
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
November 27, 2023
From
Genmab A/S
Via
Business Wire
7 Must-Buy Stocks That Are on Ridiculous Discount Now
November 13, 2023
With Wall Street still chasing after the usual suspects in the tech ecosystem, astute investors may wish to target stocks on sale.
Via
InvestorPlace
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
November 09, 2023
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)
November 02, 2023
From
Genmab A/S
Via
Business Wire
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
October 22, 2023
From
Seagen Inc.
Via
Business Wire
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
October 20, 2023
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.